AmbioDry™ Ultrastructural Characteristics Abstracted
at the Annual ARVO Research Meeting
COSTA MESA, California – 8 May 2003 –
At the annual meeting of the Association of Research in Vision and
Ophthalmology, the unique ultrastructural features of AmbioDry Amniotic
Membrane Allografts were detailed in a poster presentation by Dr.
Thomas John (Loyola University, Maywood IL, Cornea Research Center).
Various, standard histological methods were employed for analysis
including light microscopy, scanning electron microscopy and transmission
electron microscopy. The research detailed mean hydration thickness,
collagen structure and cellular distribution.
The introduction of this new AmbioDry™ dehydrated HAM adds
another dimension to amniotic membrane surgery. The absence of a
carrier sheet allows direct ocular application of this new HAM.
AmbioDry™ dehydrated HAM without intact epithelial cells and
easy handling characteristics make it a good choice for HAM transplantation.
AmbioDry Allografts, dehydrated tissue grafts derived from human
placenta, are employed by eye surgeons for the treatment of a variety
of ocular surface disorders and defects. AmbioDry Allografts are
processed in the United States in alliance with Celgene Corporation.
In comparison to competitive tissue options, the advantages of
the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life
storage; prepares in minutes for surgery; substrate-free; consistent
“Dr. Thomas John is the leader in histological examination
of amniotic membrane technologies for eye surgery. His research
data details the differentiating features of the AmbioDry and further
confirms the advantages and benefits of the technology”, stated
Erich Ziegler, President of OKTO Ophtho.
Founded in 2000, OKTO Ophtho develops and commercializes specialized,
leading-edge surgical technologies for eye surgery. OKTO’s
purpose is to develop surgical solutions that improve the quality
of life for patients, elevate the performance and productivity of
eye care professionals, and lower costs to the provider.
OKTO currently holds leadership positions with surgical devices
for oculoplastic surgeries and bio-implant technologies for ocular